Fig. 4: Validation of lead compounds from secondary drug screen on glycogen buildup phenotype. | Communications Biology

Fig. 4: Validation of lead compounds from secondary drug screen on glycogen buildup phenotype.

From: CHK1 inhibition rescues abnormal glycogen buildup in a Caenorhabditis elegans model for glycogen storage disease III

Fig. 4: Validation of lead compounds from secondary drug screen on glycogen buildup phenotype.

A Top 25 compounds from the secondary screen that significantly improved mthe edian activity of the swimming motility behavior in S1444R mutants. B Validation of top hits on glycogen buildup phenotype through iodine staining. Pimozide and Pramoxine HCl significantly decreased glycogen buildup in S1444R mutants compared to vehicle controls (n ≈ 30). A one-way ANOVA was used for B (DF = 7, F(7, 304) = 2.454). Data are presented as mean ± SEM.

Back to article page